The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016:
40 negotiations are currently underway with 10 files added since the last update of July 31, 2016:
Cotellic (cobimetinib): used to treat metastatic melanoma
Fabrazyme (agalsidase beta): used to treat ... Read More
08
Sep2016
26
Aug2016
The Canadian Association for Healthcare Reimbursement (CAHR) is hosting Market Access 201-Fundamentals of Reimbursement in Canada. This one-day training course is a continuation of Market Access 101 and offers a deeper dive into Market Access strategies. The program will be emceed by Dr. Jeffery Hoch from the Department of ... Read More
26
Aug2016
Information Session on the PMPRB Guidelines Modernization Discussion Paper
On August 23rd, 2016, PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, held a free “Information Session on the PMPRB Guidelines Modernization Discussion Paper”. This came shortly after the PMPRB recently releasing its long awaited consultation paper “PMPRB ... Read More
19
Aug2016
2015 Annual Report Released
Earlier today, the Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2015. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of ... Read More
17
Aug2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2016:
32 negotiations are currently underway with 2 files added since the last update of June 30, 2016:
Avastin (bevacizumab): used to treat genitourinary platinum-resistant ovarian cancer
Opdivo (nivolumab): used to ... Read More
29
Jul2016
PDCI’s PMPRB Guidelines Modernization Webinar Session
On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range ... Read More
12
Jul2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016:
33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016:
Abilify (aripiprazole): used for the treatment of schizophrenia and related ... Read More
04
Jul2016
On June 24, the PMPRB released its long awaited consultation paper “PMPRB Guidelines Modernization – Discussion Paper, June 2016”. The paper, the initial phase of a three-part Guideline modernization process, asserts that PMPRB’s current framework is outdated and seeks feedback on a wide range of issues that will inform ... Read More
27
Jun2016
Discussion Paper. On Friday June 24, the PMPRB released a long delayed discussion paper covering a wide range of issues that go to the core of the PMPRB’s price regulation mandate. The PMPRB will be seeking input from stakeholders over the Summer/Fall of 2016 and will hold public policy hearings ... Read More
20
Jun2016
In February 2015, PDCI Market Access (PDCI) released a report entitled pCPA Negotiation Guidelines. That report, which was a collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and PDCI, was meant to provide guidance to manufacturers on pCPA’s expectations surrounding negotiations.
Although the pCPA Negotiation Guidelines report outlined how manufacturers should ... Read More